Literature DB >> 8907816

Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer.

S Vijayakumar1, S F Quadri, L Dong, L Ignacio, I N Kathuria, H Sutton, H Halpern.   

Abstract

This cross-sectional study was undertaken to determine whether serum hormones (free testosterone, androstenedione, luteinizing hormone, or prolactin) have any influence on serum prostate specific antigen (PSA) levels in patients with stage A-C prostate cancer. Blood samples were collected prior to any treatment in 36 patients; in 19 (group 1), three blood samples were collected 10 minutes apart between 9:00 AM and 9:30 AM for each patient and pooled together to avoid diurnal and episodic variation in serum testosterone values. In the remaining patients, only one sample could be collected (group 2). Free testosterone, androstenedione, luteinizing hormone, prolactin, and PSA levels were determined with appropriate radioimmunoassay techniques. Statistical analyses were performed separately for groups 1 and 2, and then with pooled data. None of the hormones in any of the analyses showed any association to serum PSA values except for prolactin for the pooled data and for group 2. This statistical significance for prolactin disappeared on multivariate analysis. There were 21 African-American men and 15 whites in the study; no racial differences in hormonal levels were found except for lower luteinizing hormone levels in African Americans in group 2 and pooled data. No differences were found between group 1 and group 2 in the mean serum prolactin and luteinizing hormone values. Serum free testosterone, androstenedione, and luteinizing hormone appeared to have no influence on serum PSA values in nonmetastatic cancer patients. Serum prolactin values were inversely associated with PSA values in univariate analysis for the pooled data; this disappeared in multivariate analysis. Unlike other studies that found higher serum testosterone levels in African-American college students than whites, no such differences were seen in this age group. Luteinizing hormone was lower in African-American men than in whites in the pooled study population. Further studies are needed to clarify our findings.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8907816      PMCID: PMC2607949     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  18 in total

1.  Synergistic role of prolactin in response of male rat sex accessories to androgen.

Authors:  M D CHASE; I I GESCHWIND; H A BERN
Journal:  Proc Soc Exp Biol Med       Date:  1957-04

Review 2.  Endocrine control and physiology of the prostate.

Authors:  A A Sandberg
Journal:  Prostate       Date:  1980       Impact factor: 4.104

3.  The heterologous growth of cancer of the human prostate.

Authors:  M S HOVENANIAN; C L DEMING
Journal:  Surg Gynecol Obstet       Date:  1948-01

4.  Prolaction and prostate cancer.

Authors:  W E Farnsworth; M J Gonder
Journal:  Urology       Date:  1977-07       Impact factor: 2.649

5.  Improving the diagnostic reliability of rapidly fluctuating plasma hormone levels by optimized multiple-sampling techniques.

Authors:  J W Goldzieher; T S Dozier; K D Smith; E Steinberger
Journal:  J Clin Endocrinol Metab       Date:  1976-10       Impact factor: 5.958

6.  Effect of prolactin, growth hormone and insulin on the uptake and binding of dihydrotestosterone to the cultured rat ventral prostate.

Authors:  R Johansson
Journal:  Acta Endocrinol (Copenh)       Date:  1976-04

7.  Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone.

Authors:  V Petrow; G M Padilla; S Mukherji; S A Marts
Journal:  J Pharm Pharmacol       Date:  1984-05       Impact factor: 3.765

Review 8.  Metabolic epidemiology of prostatic cancer.

Authors:  E L Wynder; K Laakso; M Sotarauta; D P Rose
Journal:  Prostate       Date:  1984       Impact factor: 4.104

9.  Measurements of prolactin and androgens in patients with prostatic diseases.

Authors:  J Saroff; R Y Kirdani; T M Chu; Z Wajsman; G P Murphy
Journal:  Oncology       Date:  1980       Impact factor: 2.935

10.  The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration.

Authors:  R L Noble
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

View more
  5 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients.

Authors:  S O Asbell; K C Raimane; A T Montesano; K L Zeitzer; M D Asbell; S Vijayakumar
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

Review 3.  Biological basis of cancer health disparities: resources and challenges for research.

Authors:  Sachin K Deshmukh; Shafquat Azim; Aamir Ahmad; Haseeb Zubair; Nikhil Tyagi; Sanjeev K Srivastava; Arun Bhardwaj; Seema Singh; Rodney P Rocconi; Ajay P Singh
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

4.  Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

Authors:  Antonio B Porcaro; Filippo Migliorini; Mario Romano; Aldo Petrozziello; Stefano Zecchini Antoniolli; Emanuele Rubilotta; Vincenzo Lacola; Teodoro Sava; Claudio Ghimenton; Beatrice Caruso; Carmelo Monaco; Luigi Comunale
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

5.  Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories.

Authors:  Rhonda Arthur; Henrik Møller; Hans Garmo; Lars Holmberg; Pår Stattin; Håkan Malmstrom; Mats Lambe; Niklas Hammar; Göran Walldius; David Robinson; Ingmar Jungner; Mieke Van Hemelrijck
Journal:  Cancer Med       Date:  2016-02-29       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.